Embr Thermal Device for Hot Flash Management in Prostate Cancer

NCT ID: NCT04892914

Last Updated: 2022-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-28

Study Completion Date

2021-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Embr thermal device is a smart device that is worn on the inside of the wrist. It is about the size of a smart watch. The Embr thermal device produces cooling or warming temperature sensations that make some people feel slightly cooler or warmer. This objective of this study is to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment. The study will take place over 4 weeks. The primary outcome is feasibility of the Embr thermal device in men with prostate cancer. Secondary outcomes include preliminary efficacy of the device, which will include the change in hot flash interference sleep measures (sleep impairment and fatigue). This is a remote study--all study assessments will be completed electronically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Hot Flashes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Embr thermal device
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Embr thermal device

Use of the Embr thermal device

Group Type EXPERIMENTAL

Embr thermal device

Intervention Type DEVICE

Participants use the Embr thermal device for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Embr thermal device

Participants use the Embr thermal device for 4 weeks

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have received a diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy or orchiectomy at least 1 month prior to enrollment.
* May have received prior definitive radiation therapy or surgery (\>60 days prior to study).
* Have bothersome hot flashes (occurrence ≥ 28 times per week and at least moderately bothersome).
* Presence of hot flashes for \>30 days prior to study entry.
* Have a working smartphone (iPhone 6 or greater; or Android 8.0 or greater).
* Willing to downloading and use the Embr thermal device companion app on their phone
* Willing to wear the Embr thermal device for 4 weeks, and charge and sync the device daily
* In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English

Exclusion Criteria

* Planned treatment with chemotherapy and/or any medical intervention that will impact hot flashes, sleep, or other daily activities of daily life during the 4-week study.
* History of a known sleep disorder, other than insomnia (eg, obstructive sleep apnea, restless leg syndrome), or medical or psychiatric condition that affects sleep, or undergoing treatment for insomnia.
* History of cognitive impairment or dysfunction.
* Seizure history, history of recurrent falls, or known brain metastases.
* Uncontrolled intercurrent illness.
* Individuals with a second malignancy other than non-melanoma skin cancers.
* Individuals taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior.
* Individuals taking prescription sleep medications.
* Individuals who report consuming more than 7 alcoholic beverages/week and/or frequent alcohol consumption within 2 hours prior to bed.
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Embr Labs, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alicia Morgans, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Northwestern University Feinberg School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Embr Labs (Remote study site)

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EMBR-PC-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Focal Laser Ablation of Prostate Cancer
NCT04305925 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Fusion Guided Focal Laser Ablation of Prostate Cancer
NCT02759744 ENROLLING_BY_INVITATION NA